Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size, Share, Growth, and Industry Analysis, By Type (5-HT3 Inhibitors,NK1 Inhibitors,Other), By Application (Highly Emetogenic Chemotherapy,Moderately Emetogenic Chemotherapy,Low Emetogenic Chemotherapy,Other), Regional Insights and Forecast to 2035

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Overview

The global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market size is projected to grow from USD 2652.94 million in 2026 to USD 2785.59 million in 2027, reaching USD 4114.89 million by 2035, expanding at a CAGR of 5% during the forecast period.

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis shows that in 2023, 5-HT3 Inhibitors held about 55% of type share, NK1 Inhibitors about 30%, Other types approximately 15%. In application segments for 2023, Highly Emetogenic Chemotherapy accounted for about 45%, Moderately Emetogenic about 35%, Low Emetogenic about 15%, Other uses about 5%. Regional share in 2023: North America contributed close to 40%, Asia Pacific about 25%, Europe around 20%, Latin America 10%, Middle East & Africa about 5%. Number of cancer chemotherapy treatments globally exceeded 20 million in 2023, with many protocols including antiemetic prophylaxis in over 70% of highly emetogenic regimens.

In the USA CINV Drugs Market, approximately 40% of global CINV drug consumption occurs, with 5-HT3 Inhibitors capturing around 50-55% of US type share. Highly emetogenic chemotherapy protocols in the USA represent roughly 45% of application volume; Moderately emetogenic about 35%; Low about 15%, Other about 5%. Hospitals account for more than 60% of drug dispensation for CINV in the USA, oncology clinics about 25%, and homecare settings the remainder. Number of US patients receiving anticancer chemotherapy exceeds 1 million annually in moderate to high risk CINV categories.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Approximately 70% of chemotherapy patients experience nausea/vomiting, 55% type share of 5-HT3 Inhibitors, 30% NK1, 15% Other type usage.
• Major Market Restraint: About 15% of application in Low Emetogenic CINV, 5% in Other uses, with cost and drug access constraints in about 40% of emerging markets.
• Emerging Trends: NK1 Inhibitors acquired 30% type share, fixed-dose combination treatments comprise nearly 20% of new approvals, oral formulations emerging in over 25% of regimens.
• Regional Leadership: North America holds around 40% of type and application volume; Asia Pacific about 25%, Europe approximately 20%, Latin America 10%, Middle East & Africa 5%.
• Competitive Landscape: Top companies contribute to over 60% of NK1 and 5-HT3 inhibitor supply; “Other” types (corticosteroids, dopamine antagonists, etc.) fill roughly 15% share.
• Market Segmentation: Highly Emetogenic Chemotherapy uses about 45% of CINV drugs, Moderately Emetogenic about 35%, Low Emetogenic 15%, Other uses 5%.
• Recent Development: Over 70% of new clinical guidelines include NK1+5-HT3 combined therapy in highly emetogenic protocols; around 25% of drug approvals target fixed combinations.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Latest Trends

The Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Trends show increasing dominance of 5-HT3 Inhibitors: in 2023 these held about 55% of type share, with NK1 Inhibitors at roughly 30%, and Other drug classes around 15%. Fixed-dose combination therapies of NK1 + 5-HT3 have reached nearly 20% of new approvals, driven by efficacy in both acute and delayed CINV. Application trends reveal Highly Emetogenic Chemotherapy protocols use about 45% of drugs, Moderately Emetogenic about 35%, Low Emetogenic about 15%, Other uses about 5%.

In regional terms, North America contributes approximately 40% of CINV drug consumption globally, Asia Pacific about 25%, Europe roughly 20%, Latin America 10%, and Middle East & Africa 5%. The USA usage includes hospital settings (60% of doses), oncology clinics (25%), and home care (15%). New trend: oral formulations represent over 25% of treatment regimens, injectable settings still dominate (70%) in hospital acute CINV usage. Therapies combined with newer immunotherapy regimens are being applied in at least 30% of newly approved protocols.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Dynamics

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Dynamics refers to the interaction of forces such as drivers (rising cancer incidence and standardized prophylaxis in ~70% of chemotherapy patients), restraints (cost barriers limiting NK1 uptake in ~40% of emerging markets), opportunities (expansion of fixed-dose combinations that already account for ~20% of new approvals), and challenges (side effects and regulatory gaps affecting ~15% of patients), which collectively shape the market’s growth, therapeutic adoption, and regional distribution.

DRIVER

"Rising cancer incidence and adoption of guideline-based prophylaxis"

Global cancer cases exceeded 20 million in recent years, driving chemotherapy demand; about 70% of patients undergoing chemotherapy experience nausea/vomiting. Clinical guidelines now recommend combined NK1 + 5-HT3 + corticosteroid regimens in highly emetogenic and moderately emetogenic chemotherapy, which represent 45% and 35% of application share respectively. The adoption of fixed-dose combination NK1 + 5-HT3 therapies has reached nearly 20% of new approvals. These drivers ensure that drug classes like NK1, which had about 30% type share in 2023, are gaining increased usage in clinical settings globally and especially in North America and Asia Pacific.

RESTRAINT

"Cost barriers and limited access in low-income regions"

In many low- and middle-income countries, only approximately 5-10% of patients receive guideline-recommended NK1 inhibitors, often due to high unit cost and lack of reimbursement. “Other” drug classes, which comprise 15% of type share, are mainly used where 5-HT3 or NK1 inhibitors are unavailable or unaffordable. Access limitations reduce application use in regions beyond North America and Europe, where application share in Moderate Emetogenic and Low Emetogenic Chemotherapy is lower (e.g. < 20%) compared to developed countries. Additionally, hospital settings represent about 60% of usage in the USA, but in many countries hospital access is under 50%, limiting delivery of injectable antiemetic regimens.

OPPORTUNITY

"Development of novel formulations and expanded regional coverage"

About 25% of new formulations are oral or fixed-dose combinations, offering easier administration in outpatient or home-based care. Regions like Asia Pacific (≈ 25% of global share) and Latin America (10%) remain underserved in NK1 use, signifying opportunity for pharmaceutical companies to expand. Delayed-CINV application, at 15% share in 2023 for Low Emetogenic, and “Other” margin (5%) could be addressed via new drug classes. “Other” types currently at 15% type share may see growth with pipeline drugs. Increasing cancer treatment infrastructure in emerging economies (population centers exceeding 1 billion in several countries) magnifies opportunity.

CHALLENGE

"Drug resistance, side effects, regulatory hurdles"

Some 5-HT3 inhibitors cause QT prolongation or other side effects that lead to patient discontinuation rates in hospital settings of around 10-15%. NK1 inhibitors may produce constipation or interactions with other drugs in about 20% of patients. Regulatory approval paths vary: in some countries only 50% of NK1 drugs are reimbursed or available on national formularies. Initiation of new drug applications for “Other” classes lags; only 15% of pipeline drugs outside 5-HT3/NK1 have advanced beyond early trials.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Segmentation

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Segmentation divides the market into Type and Application to enable precise analysis and strategy; by Type the market is split into 5-HT3 Inhibitors (55% type share), NK1 Inhibitors (30%), and Other classes (15%), and by Application it is categorized into Highly Emetogenic Chemotherapy (45% of use), Moderately Emetogenic Chemotherapy (35%), Low Emetogenic Chemotherapy (15%), and Other uses such as anticipatory or breakthrough management (~5%). This segmentation facilitates assessment of therapeutic adoption, formulary penetration, dosing settings (hospital versus outpatient), and regional deployment across North America, Europe, Asia-Pacific, Latin America and MEA, enabling stakeholders to target product development, reimbursement, and commercial strategies based on measured share and clinical use patterns.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

5-HT3 Inhibitors: In 2023, accounted for about 55% of type share. Drugs like ondansetron, palonosetron dominate this class. They are used in both acute and delayed CINV, especially in combination with NK1 in about 20% of new regimens. This type class has higher utilization in hospital settings (70%) and among patients receiving highly emetogenic chemotherapy (application share ≈ 45%), Moderately Emetogenic (35%).

The 5-HT3 Inhibitors segment is valued at USD 1263.3 million in 2025, contributing 50.0% share, and is forecasted to expand at a 4.8% CAGR through 2034, remaining the backbone therapy for acute CINV management.

Top 5 Major Dominant Countries in the 5-HT3 Inhibitors Segment

• United States: Estimated at USD 379.0 million in 2025, with 30.0% share, expanding at 4.7% CAGR, supported by broad hospital adoption and strong oncology guidelines.
• China: Valued at USD 252.6 million in 2025, covering 20.0% share, advancing at 4.9% CAGR, fueled by rising chemotherapy cycles and oncology infrastructure growth.
• Germany: At USD 151.6 million in 2025, holding 12.0% share, growing at 4.8% CAGR, driven by standardized cancer care protocols across hospitals.
• Japan: Worth USD 126.3 million in 2025, representing 10.0% share, rising at 4.6% CAGR, reflecting advanced chemotherapy regimens adoption.
• India: Estimated at USD 113.7 million in 2025, contributing 9.0% share, increasing fastest at 5.2% CAGR, due to rising cancer incidence and generic drug access.

NK1 Inhibitors: Held about 30% of type share in 2023. Key drugs include aprepitant, netupitant, fosaprepitant. NK1 class increasingly used in combination with 5-HT3 and corticosteroids, especially in protocols representing about 80% of highly emetogenic chemotherapy use. Usage in regions like Asia Pacific and North America rising; in many emerging markets NK1 use still under 20%.

The NK1 Inhibitors segment is projected at USD 1010.6 million in 2025, comprising 40.0% share, and is set to grow at a 5.2% CAGR, reflecting increasing use in delayed and combination CINV protocols.

Top 5 Major Dominant Countries in the NK1 Inhibitors Segment

• United States: Market size USD 303.1 million in 2025, with 30.0% share, expanding at 5.1% CAGR, supported by high prescribing rates in oncology centers.
• China: Valued at USD 202.1 million in 2025, covering 20.0% share, growing at 5.3% CAGR, fueled by expanding cancer treatment centers.
• Japan: At USD 121.3 million in 2025, holding 12.0% share, advancing at 5.0% CAGR, reflecting wide use in delayed emesis protocols.
• Germany: Estimated at USD 101.1 million in 2025, with 10.0% share, rising at 5.1% CAGR, supported by advanced oncology guidelines.
• India: Worth USD 90.9 million in 2025, covering 9.0% share, expanding at 5.4% CAGR, boosted by patient volume and adoption of generics

Other Types: About 15% of type share in 2023, comprising corticosteroids (e.g. dexamethasone), dopamine antagonists, cannabinoid antagonists, and others. These are often used in anticipatory or breakthrough CINV, or where access to 5-HT3/NK1 classes is restricted. Usage in Low Emetogenic chemotherapy protocols (15% application) and “Other” application (5%) frequently involves “Other” drug classes.

The “Other” segment, including corticosteroids, dopamine antagonists, and cannabinoids, is valued at USD 252.6 million in 2025, representing 10.0% share, and expected to grow at a 4.5% CAGR through 2034, supporting breakthrough and rescue therapies.

Top 5 Major Dominant Countries in the Other Segment

• United States: Estimated at USD 75.8 million in 2025, with 30.0% share, expanding at 4.4% CAGR, used widely for adjunctive therapy.
• China: Valued at USD 50.5 million in 2025, covering 20.0% share, advancing at 4.6% CAGR, particularly in low-cost hospital settings.
• Germany: At USD 30.3 million in 2025, holding 12.0% share, growing at 4.5% CAGR, primarily for breakthrough nausea treatments.
• Japan: Worth USD 25.2 million in 2025, representing 10.0% share, rising at 4.3% CAGR, used for anticipatory nausea prevention.
• India: Estimated at USD 22.7 million in 2025, contributing 9.0% share, expanding at 4.8% CAGR, driven by accessibility and affordability

BY APPLICATION

Highly Emetogenic Chemotherapy: Represents approximately 45% of application usage in 2023. These protocols typically mandate triple antiemetic therapy (NK1 + 5-HT3 + corticosteroid). Most major oncology centers in North America and Europe follow these standards; about 70% of drug usage in 5-HT3 and NK1 classes is within this application segment.

This application segment is valued at USD 1137.0 million in 2025, with 45.0% share, and projected to grow at a 5.3% CAGR, as triple therapy is mandated in nearly all guidelines.

Top 5 Countries in Highly Emetogenic Chemotherapy

• United States: USD 341.1 million, 30.0% share, 5.2% CAGR, supported by adherence to NCCN guidelines.
• China: USD 227.4 million, 20.0% share, 5.3% CAGR, driven by rapid expansion of oncology centers.
• Germany: USD 136.4 million, 12.0% share, 5.1% CAGR, with broad protocol adherence.
• Japan: USD 113.7 million, 10.0% share, 5.0% CAGR, reflecting hospital-based adoption.
• India: USD 102.3 million, 9.0% share, 5.5% CAGR, due to increased chemotherapy treatments.

Moderately Emetogenic Chemotherapy: Covers roughly 35% of applications. Treatment regimens often use 5-HT3 inhibitors, sometimes with NK1 depending on guidelines. In many emerging markets this segment is growing; about 25% of new treatment approvals target moderately emetogenic chemotherapy support.

This segment is projected at USD 884.3 million in 2025, with 35.0% share, and expected to expand at a 4.9% CAGR, often involving 5-HT3 inhibitors.

Top 5 Countries in Moderately Emetogenic Chemotherapy

• United States: USD 265.3 million, 30.0% share, 4.8% CAGR, widely adopted in outpatient oncology centers.
• China: USD 176.9 million, 20.0% share, 5.0% CAGR, with rising middle-income patient base.
• Germany: USD 106.1 million, 12.0% share, 4.9% CAGR, supported by healthcare insurance coverage.
• Japan: USD 88.4 million, 10.0% share, 4.7% CAGR, reflecting widespread hospital integration.
• India: USD 79.6 million, 9.0% share, 5.2% CAGR, driven by cost-effective generic formulations.

Low Emetogenic Chemotherapy: Accounts for about 15% of application usage. Usage of 5-HT3 inhibitors dominates; NK1 seldom used in this category. Patients often treated prophylactically with single agents; hospital settings handle about 60% of low emetogenic application.

This segment is valued at USD 379.0 million in 2025, with 15.0% share, and projected to grow at a 4.5% CAGR, dominated by single-agent therapies.

Top 5 Countries in Low Emetogenic Chemotherapy

• United States: USD 113.7 million, 30.0% share, 4.4% CAGR, primarily 5-HT3 inhibitor usage.
• China: USD 75.8 million, 20.0% share, 4.6% CAGR, reflecting expansion of outpatient care.
• Germany: USD 45.5 million, 12.0% share, 4.5% CAGR, aligned with supportive care protocols.
• Japan: USD 37.9 million, 10.0% share, 4.3% CAGR, adopted in low-risk chemotherapy.
• India: USD 34.1 million, 9.0% share, 4.7% CAGR, cost-driven adoption of generics.

Other Applications (anticipatory, breakthrough, rescue): Approximately 5% of total application volume. These include cases where standard prophylactic therapy fails, or where nausea/vomiting presents outside the usual acute/delayed windows. “Other” drug classes are more prevalent here (~50% of drug usage in this sub-segment) due to need for rescue or supportive care.

The Other segment, including anticipatory and breakthrough CINV, is sized at USD 126.3 million in 2025, contributing 5.0% share, growing at a 4.2% CAGR.

Top 5 Countries in Other Applications

• United States: USD 37.9 million, 30.0% share, 4.1% CAGR, with adjunctive drug reliance.
• China: USD 25.3 million, 20.0% share, 4.3% CAGR, driven by high patient volume.
• Germany: USD 15.2 million, 12.0% share, 4.2% CAGR, focused on rescue therapy.
• Japan: USD 12.6 million, 10.0% share, 4.0% CAGR, primarily for anticipatory nausea.
• India: USD 11.4 million, 9.0% share, 4.4% CAGR, reflecting affordability of corticosteroids.

Regional Outlook for the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market

The Regional Outlook for the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market explains geographic distribution and growth patterns, where North America accounts for about 40% of global share, Asia-Pacific holds nearly 25%, Europe contributes around 20%, while Latin America represents close to 10% and the Middle East & Africa cover about 5%, reflecting differences in cancer prevalence, access to 5-HT3 and NK1 inhibitors, healthcare infrastructure, and adoption of standardized antiemetic guidelines

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America contributes about 40% of global CINV Drugs Market type and application volume in 2023. Hospitals and oncology clinics in the USA and Canada adopt guideline(s) that mandate NK1 + 5-HT3 support in almost all Highly Emetogenic Chemotherapy protocols, often covering 45% of application share. “Other” application uses account for approx 5% in North America. Within type share, 5-HT3 Inhibitors dominate (55%) followed by NK1 (30%) and Other (~15%). Oral formulations in North America account for over 25% of NK1 drug delivery in outpatient settings.

North America dominates with USD 1010.6 million in 2025, covering 40.0% share, and expanding at a 5.0% CAGR, driven by robust oncology guidelines, strong hospital infrastructure, and wide adoption of NK1 inhibitors.

North America – Major Dominant Countries

• United States: USD 757.9 million, 75.0% share, 5.0% CAGR, leading with strong adoption of combination therapies.
• Canada: USD 121.3 million, 12.0% share, 4.9% CAGR, with nationwide protocol adherence.
• Mexico: USD 80.8 million, 8.0% share, 5.1% CAGR, supported by expanding oncology services.
• Cuba: USD 30.3 million, 3.0% share, 4.8% CAGR, limited NK1 access.
• Dominican Republic: USD 20.2 million, 2.0% share, 4.7% CAGR, reliant on 5-HT3 monotherapy.

EUROPE

Europe contributes approximately 20% of global market share by type and application in 2023. Type share: 5-HT3 Inhibitors dominate (~55%), NK1 Inhibitors ~30%, Others ~15%. Application distribution: Highly Emetogenic ~45%, Moderately Emetogenic ~35%, Low Emetogenic ~15%, Other ~5%. In Western European countries, hospital settings manage over 50% of therapy administration; oral and injectable forms roughly split 30-70% depending on setting.

Europe is valued at USD 505.3 million in 2025, holding 20.0% share, and projected to grow at a 4.9% CAGR, with high use of 5-HT3 inhibitors and increasing NK1 combinations.

Europe – Major Dominant Countries

• Germany: USD 126.3 million, 25.0% share, 4.9% CAGR, leading NK1 adoption.
• United Kingdom: USD 101.1 million, 20.0% share, 5.0% CAGR, high outpatient adoption.
• France: USD 75.8 million, 15.0% share, 4.8% CAGR, supported by reimbursement.
• Italy: USD 50.5 million, 10.0% share, 4.7% CAGR, strong hospital usage.
• Spain: USD 50.5 million, 10.0% share, 4.8% CAGR, increasing NK1 adoption.

ASIA-PACIFIC

Asia-Pacific controls about 25% of global CINV Drugs Market share in 2023. In this region, access to NK1 inhibitors is lower—approx 20-25% type share—while 5-HT3 Inhibitors dominate (~55-60%) with “Other” classes together ~15-20%. Application share: Highly Emetogenic ~45%, Moderately Emetogenic ~35%, Low Emetogenic ~15%, Others 5%. Oral delivery formats are increasingly used in outpatient and homecare in Asian countries; hospital settings still dominate injectable use (70%) in acute phases.

Asia contributes USD 631.7 million in 2025, capturing 25.0% share, and forecasted to grow at a 5.2% CAGR, reflecting rising cancer incidence and expanding hospital oncology care.

Asia – Major Dominant Countries

• China: USD 252.7 million, 40.0% share, 5.3% CAGR, largest regional consumer.
• India: USD 126.3 million, 20.0% share, 5.4% CAGR, driven by patient volume.
• Japan: USD 88.4 million, 14.0% share, 5.0% CAGR, advanced oncology standards.
• South Korea: USD 63.2 million, 10.0% share, 5.1% CAGR, strong hospital compliance.
• Australia: USD 50.5 million, 8.0% share, 5.0% CAGR, robust clinical practice.

MIDDLE EAST & AFRICA

Middle East & Africa represent about 5% of global CINV Drugs Market share in 2023. Type distribution: 5-HT3 Inhibitors approx 50-55%, NK1 ~25-30%, Other types ~15-20%. Application: Highly Emetogenic ~45%, Moderately ~35%, Low ~15%, Other uses 5%. Access to NK1 inhibitors is more limited; hospitals dominate administration (70%), with clinic settings filling ~20%, home care ~10%.

Middle East & Africa are valued at USD 126.3 million in 2025, contributing 5.0% share, and expected to grow at a 4.7% CAGR, constrained by limited NK1 access but rising cancer prevalence.

Middle East & Africa – Major Dominant Countries

• Saudi Arabia: USD 31.6 million, 25.0% share, 4.8% CAGR, NK1 expanding.
• United Arab Emirates: USD 25.3 million, 20.0% share, 4.7% CAGR, leading in advanced hospital adoption.
• South Africa: USD 18.9 million, 15.0% share, 4.6% CAGR, mainly 5-HT3 usage.
• Egypt: USD 12.6 million, 10.0% share, 4.5% CAGR, limited NK1 usage.
• Nigeria: USD 12.6 million, 10.0% share, 4.6% CAGR, cost-driven reliance on Other drugs.

List of Top Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Companies

• Mylan
• Teva
• Roche
• Mundipharma
• Qilu Pharma
• Tesaro
• Heron Therapeutics
• Novartis
• Eisai
• Merck

Merck: Among the top companies with leading share in NK1 inhibitor class, contributing significantly to nearly 30% share of NK1 drug usage globally.

Novartis: Also among the highest market share companies, with strong 5-HT3 inhibitor presence, contributing to over 50% type share in many developed markets.

Investment Analysis and Opportunities

Investment in the Chemotherapy Induced Nausea and Vomiting Drugs Market is growing due to increasing cancer incidence and demand for better patient supportive care. Number of chemotherapy cycles globally exceeds 20 million per year, with roughly 70% of patients suffering nausea/vomiting. Drug developers investing in fixed-dose NK1 + 5-HT3 combinations represent nearly 20% of new approvals. Opportunities also exist in moderately and low emetogenic chemotherapy protocols which hold 35% and 15% application shares, respectively, but are underserved in NK1 usage. Emerging economies in Asia-Pacific, Latin America and MEA collectively represent around 40% of global population impact but currently only ~35% of NK1 adoption, representing investment potential. Also, formulations in oral delivery represent over 25% of regimens, suggesting investment in patient-friendly products. Hospitals deliver ~60% of CINV drugs globally, but homecare and outpatient settings are increasing; approximately 25-30% of treatments are shifting outside hospitals. Manufacturers investing in packaging, cold chain, fixed combinations, and generics can capitalize.

New Product Development

Innovation in CINV Drugs Market Research Report reveals over 20% of pipeline therapies are fixed-dose combinations combining NK1 and 5-HT3 antagonists. Several new oral formulations have been approved in recent years, representing more than 25% of new drug launches. Other drug classes (dopamine antagonists, corticosteroids beyond standard protocols) grow in usage especially in rescue settings which account for 5% of application volume. Advances include extended half-life formulations of NK1 agents to cover delayed emesis over 72 hours, used in protocols that represent ~45% application usage. Researchers also developing transdermal patches and sublingual types for patients with difficulty swallowing; these modes constitute ~10-15% of early-stage development. Biomarker and pharmacogenomic studies are underway in around 10% of trials to personalize antiemetic treatment, especially in Asia and Europe. Novel supportive care therapies (e.g. combination with anti-anxiety agents or natural adjuncts) are under investigation in ~5% of clinical studies targeting breakthrough or anticipatory nausea.

Five Recent Developments

• In 2024, clinical guidelines in major oncology societies increased recommendation of NK1 + 5-HT3 + corticosteroid regimen in over 80% of highly emetogenic chemotherapy protocols.
• A fixed-dose NK1 + 5-HT3 combination drug (netupitant/palonosetron) saw usage in ~20% of new regimen approvals in 2024.
• Oral formulations in Asia-Pacific region rose to represent over 30% of NK1 drug usage in outpatient oncology centers in 2025.
• Hospitals in North America increased adoption of delayed CINV supportive therapies (beyond 24 hours) in ~45% of cycles during 2024.
• Regulatory inclusion: more than 10 country-governments in Latin America and MEA added NK1 inhibitors to their national formulary or reimbursement list by mid-2025.

Report Coverage of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market

The Chemotherapy Induced Nausea and Vomiting Drugs Market Report covers detailed segmentation by drug type including 5-HT3 Inhibitors (55% type share in 2023), NK1 Inhibitors (30%), Other drug classes (15%). It analyzes application segments: Highly Emetogenic Chemotherapy (45%), Moderately Emetogenic (35%), Low Emetogenic (15%), Other uses (5%). Geographic coverage includes regions such as North America (40% of global consumption), Asia-Pacific (25%), Europe (20%), Latin America (10%), Middle East & Africa (5%).

Key company profiles in the report include Merck and Novartis, identified as top two firms with highest market share in NK1 and 5-HT3 inhibitor classes. The Report focuses on investment opportunities like fixed-dose combinations (~20% of new approvals), oral form innovations (>25% of new regimens), and expansion in underserved regions (Asia-Pacific, Latin America, MEA). It outlines new product development including extended-release and alternative delivery formats in ~10-15% of pipeline therapies. The report also details recent developments (as above), competitive landscape, drug approval timeline, patient adherence metrics, formulary and reimbursement status in key countries to support strategic decisions in the CINV Drugs Market Forecast, CINV Drugs Market Insights, and CINV Drugs Market Opportunities.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 2652.94 Million in 2026
Market Size Value By	USD 4114.89 Million by 2035
Growth Rate	CAGR of 5% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : 5-HT3 Inhibitors NK1 Inhibitors Other By Application : Highly Emetogenic Chemotherapy Moderately Emetogenic Chemotherapy Low Emetogenic Chemotherapy Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample